Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed a Form 8-K on June 3, 2026, reporting the entry into a material agreement. The Company entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The transaction is expected to close on June 10, 2026.
Key Financial Metrics
- Debt Issuance: $250.0 million principal amount of 2.25% Convertible Senior Notes due 2031.
- Interest Rate: 2.25% per annum, payable semiannually in arrears beginning December 15, 2026.
- Maturity Date: June 15, 2031.
- Net Proceeds: Estimated at approximately $243 million after deducting placement agent fees and expenses.
- Conversion Price: Initial conversion price of approximately $24.76 per share (40.3894 shares per $1,000 principal amount), representing a 35% premium over the last reported sale price on June 3, 2026.
- Maximum Dilution: Up to 13,631,400 shares of Common Stock may be issued upon conversion based on the initial maximum conversion rate.
Material Changes and Transaction Terms
The filing details the creation of a new direct financial obligation. The Notes are senior unsecured obligations. Key terms include:
- Conversion Conditions: Notes are convertible prior to March 15, 2031, only upon satisfaction of specific conditions, including the Company's stock price trading at or above 130% of the conversion price for 20 of 30 trading days, or if the trading price of the Notes falls below 98% of the product of the stock price and conversion rate.
- Redemption: The Company may not redeem the Notes prior to June 20, 2029. After this date, redemption is permitted if the stock price has been at least 130% of the conversion price for 20 of 30 trading days.
- Fundamental Change Repurchase: Upon a fundamental change, noteholders may require the Company to repurchase the Notes at 100% of the principal amount plus accrued interest.
- Use of Proceeds: Net proceeds will be used for general corporate purposes, including working capital, research and development, commercialization, and business development.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the use of proceeds and the terms of the Notes, which are subject to risks and uncertainties. The Notes were sold in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933. Shares issued upon conversion will be exempt under Section 3(a)(9). The Indenture includes customary covenants and events of default, including failure to pay interest or principal, failure to convert upon exercise of rights, and bankruptcy events. If certain bankruptcy events occur, the principal and accrued interest automatically become due and payable.
Investor Verification Checklist
- Verify the closing of the Private Placement on or around June 10, 2026.
- Confirm the actual net proceeds received versus the estimated $243 million.
- Monitor the Company's stock price relative to the $24.76 conversion price to assess conversion likelihood.
- Review the full Indenture (Exhibit 10.1) for specific covenants and default triggers.
- Track the Company's cash burn rate and R&D pipeline progress given the stated use of proceeds.